Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Published Online
on October 16, 2008

Stroke. 2008
Published online before print October 16, 2008, doi: 10.1161/STROKEAHA.107.510768
A more recent version of this article appeared on December 1, 2008
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
39/12/3316    most recent
STROKEAHA.107.510768v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wahlgren, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wahlgren, N.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Stroke
Related Collections
Right arrow Emergency treatment of Stroke
Right arrow Thrombolysis

Submitted on November 23, 2007
Revised on April 27, 2008
Accepted on May 20, 2008

Multivariable Analysis of Outcome Predictors and Adjustment of Main Outcome Results to Baseline Data Profile in Randomized Controlled Trials. Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST)

Nils Wahlgren MD, PhD*; Niaz Ahmed MD, PhD; Niclas Eriksson MSc; Franz Aichner MD; Erich Bluhmki PhD; Antoni Dávalos MD, PhD; Terttu Erilä MD, PhD; Gary A. Ford FRCP; Martin Grond MD; Werner Hacke MD, PhD; Michael G. Hennerici MD, PhD; Markku Kaste MD, PhD, FAHA, FESC; Martin Köhrmann MD; Vincent Larrue MD; Kennedy R. Lees MD, FRCP; Thomas Machnig MD, MBA; Risto O. Roine MD, PhD; Danilo Toni MD, PhD; Geert Vanhooren MD; for the SITS-MOST Investigators

From the Department of Neurology (N.W., N.A.), Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden; the Uppsala Clinical Research Centre (N.E.), Uppsala University, Uppsala, Sweden; Wagner-Jauregg Linz, Department of Neurology (F.A.), Linz, Austria; Boehringer Ingelheim GmbH (E.B., T.M.), Ingelheim, Germany; the Department of Neurosciences (A.D.), Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Spain; the Department of Neurology (T.E.), Tampere University Hospital, Tampere, Finland; the Freeman Hospital Stroke Service (G.A.F.), Newcastle General Hospital, UK; Kreisklinikum Siegen (M.G.), Siegen, Germany; the Department of Neurology (W.H.), University of Heidelberg, Heidelberg, Germany; the Department of Neurology (M.G.H.), University of Heidelberg, Mannheim, Germany; the Department of Neurology (M. Kaste), Helsinki University Central Hospital, Helsinki, Finland; the Stationsarzt Stroke Unit (M. Köhrmann), Neurologische Universitätsklinik Erlangen, Germany; the Department of Neurology (V.L.), l'Hôpital de Rangueil, Toulouse, France; the Acute Stroke Unit and Cerebrovascular Clinic, Division of Cardiovascular and Medical Sciences (K.R.L.), University of Glasgow, Glasgow, UK; the Department of Neurology (R.O.R.), Turku University Hospital, Turku, Finland; the Department of Neurology (D.T.), La Sapienza University, Hospital, Rome, Italy; and the Department of Neurology (G.V.), Sint Jan, Brugge, Belgium.

* To whom correspondence should be addressed. E-mail: nils.wahlgren{at}karolinska.se.

Background and Purpose—The Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST) unadjusted results demonstrated that intravenous alteplase is well tolerated and that the effects were comparable with those seen in randomized, controlled trials (RCTs) when used in routine clinical practice within 3 hours of ischemic stroke onset. We aimed to identify outcome predictors and adjust the outcomes of the SITS-MOST to the baseline characteristics of RCTs.

Methods—The study population was SITS-MOST (n=6483) and pooled RCTs (n=464) patients treated with intravenous alteplase within 3 hours of stroke onset. Multivariable, backward stepwise regression analyses (until P≤0.10) were performed to identify the outcome predictors for SITS-MOST. Variables appearing either in the final multivariable model or differing (P<0.10) between SITS-MOST and RCTs were included in the prediction model for the adjustment of outcomes. Main outcome measures were symptomatic intracerebral hemorrhage, defined as National Institutes of Health Stroke Scale deterioration ≥1 within 7 days with any hemorrhage (RCT definition), mortality, and independency as defined by modified Rankin Score of 0 to 2 at 3 months.

Results—The adjusted proportion of symptomatic intracerebral hemorrhage for SITS-MOST was 8.5% (95% CI, 7.9 to 9.0) versus 8.6% (6.3 to 11.6) for pooled RCTs; mortality was 15.5% (14.7 to 16.2) versus 17.3% (14.1 to 21.1); and independency was 50.4% (49.6 to 51.2) versus 50.1% (44.5 to 54.7), respectively. In the multivariable analysis, older age, high blood glucose, high National Institutes of Health Stroke Scale score, and current infarction on imaging scans were related to poor outcome in all parameters. Systolic blood pressure, atrial fibrillation, and weight were additional predictors of symptomatic intracerebral hemorrhage. Current smokers had a lower rate of symptomatic intracerebral hemorrhage. Disability before current stroke (modified Rankin Score 2 to 5), diastolic blood pressure, antiplatelet other than aspirin, congestive heart failure, patients treated in new centers, and male sex were related to high mortality at 3 months.

Conclusions—The adjusted outcomes from SITS-MOST were almost identical to those in relevant RCTs and reinforce the conclusion drawn previously in the unadjusted analysis. We identified several important outcome predictors to better identify patients suitable for thrombolysis.


Key words: monitoring • multivariate • safety • stroke • thrombolysis




This article has been cited by other articles:


Home page
StrokeHome page
K. Toyoda, M. Koga, M. Naganuma, Y. Shiokawa, J. Nakagawara, E. Furui, K. Kimura, H. Yamagami, Y. Okada, Y. Hasegawa, et al.
Routine Use of Intravenous Low-Dose Recombinant Tissue Plasminogen Activator in Japanese Patients: General Outcomes and Prognostic Factors From the SAMURAI Register
Stroke, November 1, 2009; 40(11): 3591 - 3595.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
B. Cucchiara, S. E. Kasner, D. Tanne, S. R. Levine, A. Demchuk, S. R. Messe, L. Sansing, K. R. Lees, P. Lyden, and for the SAINT Investigators
Factors Associated With Intracerebral Hemorrhage After Thrombolytic Therapy for Ischemic Stroke: Pooled Analysis of Placebo Data From the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II Trials
Stroke, September 1, 2009; 40(9): 3067 - 3072.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
N. Ahmed, N. Wahlgren, M. Brainin, J. Castillo, G. A. Ford, M. Kaste, K. R. Lees, D. Toni, and for the SITS Investigators
Relationship of Blood Pressure, Antihypertensive Therapy, and Outcome in Ischemic Stroke Treated With Intravenous Thrombolysis: Retrospective Analysis From Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR)
Stroke, July 1, 2009; 40(7): 2442 - 2449.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
E. Meseguer, M. Mazighi, J. Labreuche, C. Arnaiz, L. Cabrejo, T. Slaoui, C. Guidoux, J.-M. Olivot, H. Abboud, B. Lapergue, et al.
Outcomes of Intravenous Recombinant Tissue Plasminogen Activator Therapy According to Gender: A Clinical Registry Study and Systematic Review
Stroke, June 1, 2009; 40(6): 2104 - 2110.
[Abstract] [Full Text] [PDF]